Syndax Pharmaceuticals 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Syndax reported third-quarter 2026 total revenue of $83.3 million, up 82% year over year, including RevuForge net revenue of $60.7 million and Niktimvo collaboration revenue of $22.6 million.
- RevuForge net revenue increased 90% year over year and 11% quarter over quarter; new patient starts rose approximately 20% quarter over quarter to about 300, and total prescriptions were approximately 1,700.
- Management said RevuForge accounted for more than 35% of its $61 million quarterly net revenue from NPM1 patients, while claims data showed approximately 40% of NPM1 patients proceeded to transplant and about 50% of those patients resumed therapy.
- For KMT2A patients, approximately 50% proceeded to transplant and about 60% resumed therapy afterward, up from about 50% last quarter.
- Niktimvo net revenue was $67 million, up 47% year over year and 12% quarter over quarter; more than 300 new patients were added and about 6,350 infusions were administered.
- Syndax ended the quarter with $551 million in cash equivalents and investments.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, everyone, and welcome to the Syndax third quarter 2026 earnings conference call. Today's call is being recorded. If you'd like to ask a question following the company's prepared remarks, please press star 5 during the call. At this time, I would like to turn the call over to Sharon Klahre, head of investor relations at Syndax Pharmaceuticals.
Thank you, operator. Welcome, and thank you all for joining us today for a review of Syndax's third quarter 2026 financial and operating results. I'm Sharon Klahre, and with me this afternoon to provide an update on the company's progress and discuss financial results are Michael Metzger, Chief Executive Officer, Steve Closter, Chief Commercial Officer, Dr. Nick Botwood, Head of R&D and Chief Medical Officer, and Keith Goldan, Chief Financial Officer. This call is accompanied by a slide deck that has been posted on the investor page of the company's website. You can now turn to our forward-looking statements on slide 2. Before we begin, I'd like to remind you that any statements made during this call that are not historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by these statements as a result of various important factors, including those discussed in the risk factor section in the company's most recent quarterly report on Form 10-Q, as well as other reports filed with the SEC. Any forward-looking statements made represent our views as of today, November 2nd, 2026, only. A replay of this call will be available on the company's website, www.syndax.com, following its completion. With that, I am pleased to turn the call over to Michael Metzger, Chief Executive Officer of Syndax.
Thank you, Sharon, and good afternoon, everyone. Let's start on slide 3. Syndax delivered another strong quarter of commercial growth and pipeline momentum. Total revenue reached $83 million this quarter, up 82% year-over-year. Demand for both medicines is robust, and we are moving decisively towards profitability. Revuforj net revenue grew to $61 million in the third quarter, underscoring our market leadership in both relapse refractory NPM1 and KMT2A acute leukemia. Similar to prior quarters, we expect Revuforj to account for the vast majority, more than 80%, of the revenue for the class this quarter, a leading position we intend to carry forward. We achieved our seventh consecutive quarter of double-digit quarter-over-quarter Revuforj net revenue growth, driven by a 20% increase in new patients and an increasing number of patients resuming Revuforj after stem cell transplant.
Notably, a growing number of both KMT2A and NPM1 patients are proceeding to transplant after receiving Revuforj. As patients pause treatment to receive a transplant, this creates a short-term headwind that will become a long-term tailwind as more patients resume therapy post-transplant, extending the average duration of therapy and driving durable growth for the franchise. Every indicator of Revuforj demand is positive. The latest data are clear. We continue to lead new menin inhibitor starts across every age group, including age groups where NPM1 is predominant. With an unmatched body of clinical trial and real-world evidence and two years of deep clinician experience in the commercial setting, we are confident Revuforj will remain the menin inhibitor of choice for all menin-dependent acute leukemias.
The clinical impact of our medicine was showcased last week when Revuforj received the prestigious Best Product for Rare Orphan Diseases Award from The Galien Foundation, on the heels of being recognized by TIME as one of the best innovations of 2026. These awards are a testament to our leadership in menin inhibition and the profound difference we have made for patients with some of the most aggressive forms of acute leukemia. Looking ahead, multiple value-driving Revuforj milestones are on deck. As in prior years, Revuforj will have a leading presence at the American Society of Hematology, or ASH, annual meeting in December. New data will be presented from multiple clinical trials and real-world studies spanning the entire acute leukemia treatment continuum, including new frontline combination data that highlight the potential for our ongoing pivotal frontline trials to deliver transformative results.
We remain well-positioned to be the first to frontline with a menin inhibitor, an area of high unmet need and substantial commercial opportunity. With anticipated frontline indications, we expect Revuforj could exceed $2 billion in peak annual net revenue in the U.S. alone. Nearer term, we expect to publish Revuforj data in relapse refractory NUP98 rearranged acute leukemia in the fourth quarter. This landmark publication will inform clinical practice and could support guideline inclusion in a patient population with high unmet need. NUP98 rearrangements, estimated to be found in approximately 2% to 5% of AML cases, are associated with a poor prognosis and resistance to conventional therapies. No targeted treatments have been approved for these patients.
As the first and only company to report clinical activity with a menin inhibitor in this subtype, we have a unique opportunity to pursue a guideline listing that could meaningfully expand the patient population treated with Revuforj. Turning to Niktimvo in chronic graft-versus-host disease, or GVHD. Niktimvo net revenue grew to $67 million in the third quarter, up 47% year-over-year and 12% quarter-over-quarter. Our 50% share of Niktimvo net profit delivered $23 million in collaboration revenue, a meaningful contribution to our bottom line. Collaboration revenue to Syndax is now annualizing at over $90 million, and we expect it to keep growing as we further penetrate fourth and third line chronic GVHD. Positive results from the ongoing combination trials of Niktimvo and frontline chronic GVHD could set a new treatment paradigm and unlock another multi-billion dollar opportunity in the near term.
Beyond moving Revuforj and Niktimvo into earlier lines of treatment, we are advancing our mutant selective allosteric EGFR inhibitor for non-small cell lung cancer and our next generation menin inhibitor for myelofibrosis. Backed by compelling preclinical data and mechanistic insights, both molecules are on track to enter the clinic next year. Each brings a novel mechanism of action to diseases with high unmet need, where we can efficiently generate clinical data that inform and de-risk further development. We took our first two medicines from IND to FDA approval in about five years, and we will leverage that experience to bring innovation to new areas. With a pipeline of promising programs, world-class R&D capabilities, and a solid financial position, Syndax is poised to deliver breakthroughs that improve outcomes for patients and build long-term value.
Before I turn the call over to Steve, I want to sincerely thank Keith Goldan for his many contributions, including leading Syndax's financial and capital strategy during an important time in the company's history and spearheading numerous long-term growth initiatives. After more than four years at the company and over 30 years in the industry, Keith Goldan has decided to retire as Chief Financial Officer. I am pleased to welcome Aaron Ondrey as our new CFO, effective Monday, November 9th. Aaron brings extensive financial and operational leadership experience in biopharmaceutical companies spanning financial management, corporate strategy, and commercialization. I will now turn the call over to Steve to discuss our commercial results in more detail.
Steve. Well, thank you, Michael.
Starting with Revuforj on slide four. We delivered strong third quarter Revuforj results with double-digit quarter-over-quarter growth across all key demand metrics and growing commercial momentum. Net revenue totaled $61 million, up 90% year-over-year and 11% quarter-over-quarter. We expect Revuforj to account for the vast majority of all menin inhibitor sales this quarter, highlighting our position as the clear market leader in menin now and well into the future. Total prescriptions were approximately 1,700, up 13% quarter-over-quarter, primarily driven by growth in new patients and an expanding number of patients on therapy in the post-transplant setting. Compared to Q3 of last year, prescription volume has doubled, highlighting the robust business we are building with multiple drivers. As we expected, new starts returned to growth with about 300 new patients this quarter, up approximately 20% quarter-over-quarter.
This increase reflects growth in both new NPM1 and KMT2A patients and creates strong momentum heading into the end of this year. As highlighted on slide five, we estimate that about 50% of new Revuforj patients this quarter were NPM1 patients. Between the new patients and those who started in prior quarters, we estimate our NPM1 business accounted for more than 35% of the $61 million in net revenue this quarter. That is up more than 30% of our net revenue last quarter. Importantly, claims and prescription data indicate we continue to have dominant share of all patients starting a menin inhibitor. Notably, Medicare data show Revuforj accounted for the majority of new patients in the third quarter, as well as all prior quarters. This dataset provides a view of the split of new patients in an age group that is predominantly NPM1.
Claims data also show we continue to have the dominant share of new patients in all age groups, not just the 65 and older group. Turning to the right side of the slide and the latest treatment patterns, as we add more NPM1 patients to our mix, we continue to see Revuforj used early in the relapse refractory treatment paradigm and often in combination with other therapies. Claims data show 75% of use in the second and third line, and approximately 40% of use is in combination. Notably, we are observing robust transplant rates amongst both relapse refractory NPM1 and KMT2A patients treated with Revuforj. While 11% of NPM1 patients in our pivotal trial underwent a transplant following treatment with Revuforj, recent claims data indicate that about 40% of our NPM1 patients are proceeding to transplant, of which about 50% have resumed therapy afterward.
The transplant rate observed with Revuforj is very encouraging and highlights the clinical value of having a medicine with a high overall response rate, or ORR. A high ORR is meaningful because it provides increased chance of being able to proceed to a stem cell transplant, the only potentially curative treatment for relapse refractory NPM1 and KMT2A patients. Notably, approximately one out of two NPM1 patients achieved an overall response in the pivotal trial of Revuforj, a result others have not matched. Importantly, the ORR observed with Revuforj was also clinically meaningful for patients who are not candidates to receive a transplant. Turning to KMT2A. Claims data indicate that approximately 50% of KMT2A patients are proceeding to transplant, of which about 60% have resumed therapy afterward, up from about 50% last quarter.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
17 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
